The euro appreciated towards $1.09 in afternoon trading on Monday, as risk-on moods returned to the markets following news that Moderna (MRNA.US) experimental vaccine to treat COVID-19 had positive results during its first human trial. Investors also digest recent Fed Chair comments and the fact that Fitch lowered the outlook on France's AA rating to negative from stable, citing the substantial worsening in public finances and economic activity expected this year due to the ongoing pandemic.
The EURUSD has continued its run to the upside and managed to broke above the high from Friday. Should upbeat moods prevail, key resistance at 1.09 may come into play. On the other hand, once sellers regain control, the support at 1.0837 may be at risk. Source: xStation5
Tech review: earnings take centre stage as Apple reaches record high
IBM and Groq join forces to revolutionize AI processing
US Defense Industry Preview - Has it reached its peak?
Waymo: Race against the regulators
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
